Welcome to our dedicated page for Avalon GloboCare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalon GloboCare Corp. filings document public-company disclosures for its consumer diagnostics, generative AI software, intellectual property, and capital structure. Recent 8-K reports cover material events involving Avalon Quantum AI LLC, the Catch-Up AI video platform, Nasdaq listing-compliance notices, shareholder communications, and pro forma financial information tied to the completed sale of Avalon RT 9 Properties, LLC.
The company’s proxy and registration filings describe board elections, auditor ratification, equity incentive-plan matters, advisory compensation votes, Nasdaq-rule approvals for warrant share issuance, and securities registration matters. Avalon’s filings also address common stock, warrants, pre-funded warrants, shareholder voting mechanics, governance procedures, operating and financial results, and risk disclosures for a smaller reporting company.
Avalon GloboCare Corp. is registering for resale up to 19,436,278 shares of Common Stock held by selling stockholders, including common shares and shares issuable upon exercise of various warrants.
The Company will not receive proceeds from resale by the selling stockholders, although cash proceeds could be received if warrants are exercised in cash — full exercise of the 18,946,081 warrant shares referenced would yield approximately $6.7 million in gross proceeds. The prospectus also discloses a Nasdaq minimum bid-price noncompliance notice (closing bid $0.4490 on April 17, 2026) and the company’s ongoing going-concern uncertainty driven by operating losses and a working-capital deficit.
Avalon GloboCare Corp. is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026 at 9:00 a.m. Eastern Time. Holders of 8,323,609 shares of common stock outstanding as of April 15, 2026 can vote online, by phone, mail, or during the webcast.
Stockholders will elect four directors, ratify M&K CPAS, PLLC as auditor for 2026, approve the 2026 Stock Incentive Plan, and cast an advisory Say-on-Pay vote on 2025 executive compensation. They are also asked to approve, under Nasdaq Listing Rule 5635(d), Series A-1 warrants to purchase up to 6,372,550 shares, Series A-2 warrants to purchase up to 6,372,550 shares, placement agent warrants to purchase up to 318,628 shares, and the related common shares issued in a February 27, 2026 private placement, plus authorize a reverse stock split at a ratio between 1-for-2 and 1-for-25 without reducing authorized shares.
The board unanimously recommends voting FOR all six proposals and has retained Campaign Management as proxy solicitor.
Avalon GloboCare Corp. received a notice from Nasdaq that its common stock no longer meets the Nasdaq Capital Market minimum bid price requirement of $1.00 per share, after trading below that level for 30 consecutive business days through April 14, 2026.
The stock remains listed under the symbol ALBT, but the company has 180 days, until October 12, 2026, to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days. If it still does not comply, Avalon may qualify for an additional 180‑day period if it meets other Nasdaq listing standards and may consider actions such as a reverse stock split to cure the deficiency.
Avalon GloboCare Corp. has filed a resale registration covering up to 19,436,278 shares of common stock for existing investors. These consist of 490,197 already-issued shares plus shares underlying pre-funded warrants, Series A-1 and A-2 warrants, and placement agent warrants issued in a February 2026 private placement.
The company will not receive proceeds from investors’ resale of these shares, but could receive about $6.7 million if 18,946,081 warrant shares are fully exercised for cash. Shares outstanding were 8,323,609 as of April 8, 2026 and would be 27,759,887 if all registered warrants are exercised. The filing also highlights a history of substantial losses, a $105.9 million accumulated deficit, minimal cash, and an auditor going-concern warning, underscoring the need for additional capital.
Avalon Globocare Corp. set its 2026 Annual Meeting of Stockholders for June 9, 2026, to be held virtually. Stockholders of record as of May 15, 2026 may vote at the meeting. The company also established April 12, 2026 as the deadline for shareholder proposals and director nominations.
Proposals for inclusion in the company’s proxy materials must meet the requirements of Rule 14a-8 and be received by the Corporate Secretary by April 12, 2026. Other proposals or director nominations must also comply with SEC rules, Delaware law and the company’s Amended and Restated Bylaws, or they will not be considered.
Avalon GloboCare Corp. explains that its shareholders approved several proposals related to the company’s capital structure and financing flexibility, including authorizing the Board to implement a reverse stock split in the future if deemed appropriate. The company states this approval does not mean a reverse stock split is being implemented now and that there is currently no reverse stock split planned.
Avalon describes this authorization as a standard governance measure intended to preserve flexibility as it evaluates strategic and corporate priorities, while emphasizing continued focus on executing its business strategy. The company also highlights that it uses social media channels on Stocktwits, X, Yahoo Finance and Reddit to share public information that may be considered material and encourages interested parties to review updates posted there.
Avalon Globocare Corp. stockholders approved seven proposals at a special meeting where 2,498,866 common shares were represented, constituting a quorum. Approvals covered share issuances tied to July 2025 convertible notes, a December 2025 bridge note with 100,000 commitment shares, and conversion of Series C Convertible Preferred Stock.
Stockholders also approved exchanging 5,000 shares of Series D Convertible Preferred Stock held by the board chairman for 2,074,689 common shares, issuing 450,000 restricted common shares under a consulting agreement, and granting the board authority to implement a reverse stock split between 1-for-2 and 1-for-25 without reducing authorized shares. Adjournment authority, if needed, was also approved.